Resources

• Category: Huntingtons Disease, Alzheimers disease
• Date: 27/02/2025

Contract Wins in Alzheimer’s and Huntington’s Disease

27 February 2025 - London, UK. IXICO plc (AIM: IXI, “IXICO” or “the Company”) a global leader in neuroscience imaging, using its AI-driven platform to help advance therapy research in neurological disorders, today announces that it has signed a new commercial contract for a global Alzheimer’s Disease (AD) imaging analysis with a leading biotechnology company, and secured an additional project in Huntington’s Disease (HD) with an existing partner.

• Category: Huntingtons Disease, HD-IH, CHDI
• Date: 12/02/2025

Huntington’s Disease consortium further validates IXICO’s AI imaging platform

12 February 2025 - London, UK. IXICO plc (AIM: IXI, “IXICO” or “the Company”) a global leader in neuroscience imaging, using its AI-driven platform to help advance drug development in neurological disorders, today announces, the generation of further evidence verifying the superiority of the ‘IXIQ.Ai’ analysis platform in the development and validation of imaging biomarkers for Huntington’s Disease (HD), in conjunction with the Huntington’s Disease Imaging Harmonisation (“HD-IH”) consortium.

• Date: 16/12/2024

Commercial agreement with PETNET Solutions Inc, a Siemens Healthineers Company

16 December 2024 - London, UK. IXICO plc (AIM: IXI, “IXICO” or “the Company”) a global leader in neuroscience imaging, using its AI-driven platform to help advance therapy research in neurological disorders, today announced a commercial agreement with PETNET Solutions Inc, a Siemens Healthineers company (“PETNET”) to supply diagnostic imaging agents to IXICO. This new offering is an integral part of IXICO’s expansion strategy to serve its growing customer base with the latest technologies in neuroimaging.

• Category: Huntingtons Disease
• Date: 10/12/2024

US Client Clinical Trial Contract Win

10 December 2024 - London, UK. IXICO plc (AIM: IXI, “IXICO” or “the Company”) a global leader in neuroscience imaging, using its AI-driven platform to help advance therapy research in neurological disorders, today announces that it has signed a contract with a new US headquartered client to provide imaging services for a Phase 2 Huntington’s Disease clinical trial.

Neurological Disorders - Harmonisation of Imaging in Clinical Trials

Fully automatic detection and quantification of new white matter lesions using deep learning

Accurate detection, segmentation, and quantification of lesion dynamics in longitudinal MRI is crucial for monitoring disease progression in Multiple Sclerosis, and for evaluating the efficacy of therapeutic interventions. We present an efficient, automatic method utilising deep learning to assess lesion changes in FLAIR MRI with a high degree of accuracy.

Neuroimaging to Facilitate Clinical Trials in Huntington’s Disease: Current Opinion from the EHDN Imaging Working Group - IOS Press

This comprehensive overview of the roles of structural, functional, and diffusion MRI, PET, MRS, and MEG serves as a resource for effectively integrating neuroimaging methodologies into the design and execution of Huntington's disease clinical trials. The paper discusses their applications in patient selection, safety monitoring, and demonstrating efficacy.

Volumetric change across the different Stages of the Huntington’s disease Integrated Staging System (HD-ISS) defined at baseline

The HD Integrated Staging System enables classification of people with HD into four disease stages based on quantitative landmark assessments. Here we characterized volume change over time in the caudate nucleus, putamen, lateral ventricles, and whole-brain across participants starting in each of the different HD-ISS Stages at baseline and compared to healthy controls.